Saturday, June 25, 2022

Shareholder Confidence Builds on US Stem Cell Inc (OTCMKTS:USRM)

US Stem Cell Inc (OTCMKTS:USRM) shares have been a solid performer in 2017, since the February bottom shares have moved steadily higher. USRM stock is up huge for the year moving more than 10x higher since January.

The internal restructuring of the balance sheet and cleaning the decks has brought new confidence to investors. They are also adding board members with solid business backgrounds to assist in leadership roles. All of these changes are affecting shares positively.

US Stem Cell Inc (OTCMKTS:USRM) (formerly Bioheart, Inc.) is in the regenerative medicine and cellular therapy industry who are focused on the commercialization of cell based therapeutics that treat disease by repairing and replacing damaged or aged tissue restoring their normal function.

Many who follow this space believe regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases, lessening patient burdens, as well as reducing the associated economic impact disease imposes upon modern society.

Find out when $USRM stock reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

$USRM 10-Day Chart Below:

Working with physician partners to offer over 30 protocols to patients, U.S. Stem Cell, Inc. is increasing business opportunities by expanding its services, treatments, and therapies both inside and outside the United States.

 “U.S. Stem Cell, Inc. continues to increase revenue, decrease liabilities, and decrease operating expenses,” said Mike Tomás, President and CEO of U.S. Stem Cell, Inc. “As a world leader in stem cell research and development for degenerative conditions, we are excited about the industry’s future and dedicated to making a positive impact in our patients’ lives.”

Financial highlights from 2016 include:

  • Revenue up by 38% from $2.2M in 2015 to $3.03M in 2016
  • Current liabilities down by $1.9M, or 23.8%, from $8.0M in 2015 to $6.1M in 2016
  • Operating Expenses down 16.5% (or $631,825) from 3.82M in 2015 to $3.19M in 2016
  • Net loss improved 136% from $2.6M (gain) in 2015 to $1.15M in 2016
  • And for the first time in the company’s history, U.S Stem Cell, Inc. ended the year on a cash positive note: $108,596 cash positive as a result of operations in 2016 compared to $844,690 cash negative from operations in 2015.

The business includes three operating divisions (US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic). These encompass the development of proprietary cell therapy products, as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from the businesses will, over time, provide funds to support clinical development activities as for general business operations.

Those who follow the stock believe the combination of a therapeutics pipeline, combined with revenue generating capabilities, provides the Company with a unique opportunity for growth and a pathway to profitability. U.S. Stem Cell, Inc., announced on March 7, that Greg Knutson, the Manager of NorthStar Biotech, LLC, has joined the Board of Directors.

“We are very pleased that Greg Knutson, a longtime supporter of the U.S. Stem Cell family of companies, has agreed to join our Board and assist us to continue with our recent technological advances and financial accomplishments,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. A longtime U.S. Stem Cell shareholder and supporter, Knutson brings more than 30 years of business and financial experience to the organization.

Share prices seem to match internal changes going on within the company. Stem Cell technology is known by investors as an important sector for our aging population. It’s important to keep in mind, these stocks can be volatile and difficult to figure out for market watchers. U.S. Stem Cell, Inc. (OTCMKTS:USRM) has addressed the issues and shares have reflected these changes in the internal balance sheet structure.

The stock has moved up nicely since we covered them last, and it is important to keep in mind they are up nearly 10x for the year rallying from a triple zero sub penny to more than 10 cents. USRM a stock to watch, as it encompasses the needs of the baby boomer generation who are also investors in the stock itself. For continuing coverage on shares of $USRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Related Articles



Please enter your comment!
Please enter your name here

Stay Connected


Latest Articles